Company patents
UNIVERSITÄT BERN
UNIVERSITÄT BERN's patent strategy reveals a strong, albeit fluctuating, focus on pharmaceutical innovation, with Therapeutic Activity (35.7% of portfolio) and Pharmaceutical Preparations (33.9%) being core areas. While Peptides & Proteins saw an impressive 700.0% YoY growth in 2024, its subsequent decline in 2025 by 62.5% suggests a dynamic, perhaps exploratory, approach to emerging biotech fields, with a partial recovery so far in 2026 (YoY +33.3%).
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
56 US filings (since 2023) · 11 categories · 24 themes
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Techniques and apparatus for cultivating cells in three-dimensional structures, including organoids, tissue models, and scaffolds, often involving microfluidics, specialized matrices, or mechanical stimulation to mimic in vivo conditions.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Systems and methods for automated monitoring and dynamic adjustment of environmental parameters (e.g., pH, temperature, oxygen, nutrients) and fluid handling within bioreactors to optimize cell/tissue growth or product synthesis.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Systems and methods that use imaging technologies, computer vision, and augmented reality to provide real-time guidance, localization, and visualization during surgical procedures or for detailed anatomical assessment.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Development of devices and methods for non-invasive or minimally invasive collection and analysis of physiological data, often from wearable sensors, to monitor health, activity, or specific conditions.
Therapeutic application of electrical signals to nerves or tissues to modulate their activity, often using implantable devices, electrodes, and sophisticated programming for various conditions.
Methods and apparatus for measuring magnetic fields or utilizing magnetic resonance principles for medical diagnostics, material analysis, or precise localization, including gradient field measurement in MRI.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Development of novel materials, surface patterns, or structural supports designed to enhance cell adhesion, proliferation, differentiation, or tissue formation, including hydrogels and patterned surfaces.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Techniques for identifying microorganisms, assessing their viability, quantifying their presence, profiling their metabolic activity, or determining their susceptibility to antimicrobial agents, often in complex biological or environmental samples.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Use of alternating electric or magnetic fields at specific frequencies and intensities to achieve therapeutic effects, such as inhibiting cell proliferation (e.g., cancer) or modulating cytokine production.
Patents
Showing 41-50 of 81